Avant Diagnostics (AVDX) Out Front in Early Detect
Post# of 104
Posted On: 12/02/2015 5:07:20 PM
Avant Diagnostics (AVDX) Out Front in Early Detection and Screening for Ovarian Cancer
Avant Diagnostics (OTC: AVDX) is a leading medical technology company focused on advancing innovative solutions that improve upon the ways we screen for ovarian cancer. AVDX’s energy and resources aim to bring to market innovative diagnostic tests based upon the completion of the human genome sequencing project. The company works at developing a sophisticated screening test for diagnosing ovarian cancer using OvaDx® – a unique large-panel biomarker screening test for this deadly disease.
OvaDx is an advanced diagnostic test used specifically for measuring the activation of the immune system in response to ovarian tumor cell development. Patient sera are used in conjunction with OvaDx microarrays, which enable binding between proteomic biomarkers in the patient samples and capture agents on the microarrays. In this process, the microarrays are washed and scanned to produce a digital readout for each serum sample. From this point, the data are quantified and analyzed using software to produce the results of the test.
AVDX’s discovery path comes by way of ten years of genetic and physiological research. Avant Diagnostics concentrates on leveraging the human immune system for early detection. As a result, OvaDx delivers a large panel of refined markers for high sensitivity. The company’s proprietary OvaDx markers and kits include patented manufacturing technology, as well as a worldwide license. Following FDA 510(k) clearance, the company plans to license OvaDx for sale. Avant’s business plan looks to use its position as a public company to expand its portfolio of diagnostic tests going forward.
Genetic research is predominantly centered on identifying the variations of the specific genes in the genome. These variations define individual characteristics, including disease states or a statistical propensity for disease. The implications are far-reaching and impact not only the research community, but also the individual patients and care providers. Diagnostic tests that detect diseases very early in their progression will provide options for earlier treatments that show promise of improving quality of life and prognosis by delaying or preventing disease progression. It has been noted that medical providers will realize major cost savings by avoiding costly treatments at late stages.
For more information, visit www.avantdiagnostics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Avant Diagnostics (OTC: AVDX) is a leading medical technology company focused on advancing innovative solutions that improve upon the ways we screen for ovarian cancer. AVDX’s energy and resources aim to bring to market innovative diagnostic tests based upon the completion of the human genome sequencing project. The company works at developing a sophisticated screening test for diagnosing ovarian cancer using OvaDx® – a unique large-panel biomarker screening test for this deadly disease.
OvaDx is an advanced diagnostic test used specifically for measuring the activation of the immune system in response to ovarian tumor cell development. Patient sera are used in conjunction with OvaDx microarrays, which enable binding between proteomic biomarkers in the patient samples and capture agents on the microarrays. In this process, the microarrays are washed and scanned to produce a digital readout for each serum sample. From this point, the data are quantified and analyzed using software to produce the results of the test.
AVDX’s discovery path comes by way of ten years of genetic and physiological research. Avant Diagnostics concentrates on leveraging the human immune system for early detection. As a result, OvaDx delivers a large panel of refined markers for high sensitivity. The company’s proprietary OvaDx markers and kits include patented manufacturing technology, as well as a worldwide license. Following FDA 510(k) clearance, the company plans to license OvaDx for sale. Avant’s business plan looks to use its position as a public company to expand its portfolio of diagnostic tests going forward.
Genetic research is predominantly centered on identifying the variations of the specific genes in the genome. These variations define individual characteristics, including disease states or a statistical propensity for disease. The implications are far-reaching and impact not only the research community, but also the individual patients and care providers. Diagnostic tests that detect diseases very early in their progression will provide options for earlier treatments that show promise of improving quality of life and prognosis by delaying or preventing disease progression. It has been noted that medical providers will realize major cost savings by avoiding costly treatments at late stages.
For more information, visit www.avantdiagnostics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)